Author

Yacine Salhi

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

2009 · Joaquim Bellmunt, Christine Théodore, et al. · Journal of Clinical Oncology · 770

PDF

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

2010 · Joaquim Bellmunt, Toni K. Choueiri, et al. · Journal of Clinical Oncology · 454

Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients

2004 · A. Yovine, M. Riofrio, et al. · Journal of Clinical Oncology · 310

GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis

2019 · Emma Guttman-Yassky, Ana B. Pavel, et al. · Journal of Allergy and Clinical Immunology · 223

PDF

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy

2013 · J. Bellmunt, R. Fougeray, et al. · Annals of Oncology · 176

Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy

2010 · Maciej Krzakowski, Rodryg Ramlau, et al. · Journal of Clinical Oncology · 77

Serum Ferritin, Desferrioxamine, and Evolution of HIV-1 Infection in Thalassemic Patients

1998 · Y. Salhi, D. Costagliola, et al. · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · 65

Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function

2021 · Sunil M. Jain, Ramanathan Balamurugan, et al. · Pain · 63

Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis

2023 · Barbara Rewerska, Lawrence D. Sher, et al. · Journal of Allergy and Clinical Immunology Global · 50

Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis

2019 · Charles P. Andrews, Dale Mohar, et al. · Annals of Allergy Asthma & Immunology · 50

PDF

A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma

2013 · Gregory R. Pond, Neeraj Agarwal, et al. · British Journal of Urology · 35

Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design

2013 · Gregory R. Pond, Joaquim Bellmunt, et al. · Clinical Genitourinary Cancer · 23

Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine

2011 · Katherine M. Krajewski, Ronan Fougeray, et al. · European Journal of Cancer · 21

PDF

Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers

2018 · M. Wermke, J. Alt, et al. · Annals of Oncology · 20

Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.

2018 · Joshua Ryan Richter, Carl Ola Landgren, et al. · Journal of Clinical Oncology · 20

Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma.

2018 · Joshua Ryan Richter, Martin Wermke, et al. · Journal of Clinical Oncology · 18

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

2022 · Sanjay R Mohan, Cristiana Costa Chase, et al. · Blood · 14

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine

2013 · L C Harshman, R Fougeray, et al. · British Journal of Cancer · 12

PDF

Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.

2018 · Martin Wermke, Juergen Alt, et al. · Journal of Clinical Oncology · 10

Long-Term Nonprogression in HIV Infection

1997 · Yacine Salhi, Dominique Costagliola · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · 8

A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.

2017 · Martin Wermke, Helmuth Schmidt, et al. · Journal of Clinical Oncology · 6

13 Updated Survival Results of the Phase Iii Trial Comparing Vinflunine (v) to Best Supportive Care (bsc) in Advanced Transitional Cell Carcinoma of the Urothelium (tccu) After Failure of a Prior Platinum-containing Regimen

2010 · S. Culine, C. Lucas, et al. · European Urology Supplements · 6

472 Telazorlimab in atopic dermatitis: Phase 2b study shows improvement at 16 weeks

2021 · L. Sher, B. Rewerska, et al. · Journal of Investigative Dermatology · 5

PDF

453 GBR 830 induces progressive and sustained changes in atopic dermatitis biomarkers in patient skin lesions

2018 · E. Guttman-Yassky, A.B. Pavel, et al. · Journal of Investigative Dermatology · 5

1094 Clinical pharmacokinetics and immunogenicity of GBR 830, a first-in-class humanized monoclonal antibody inhibiting OX40 to treat atopic dermatitis

2018 · G. Gudi, V.C. A, et al. · Journal of Investigative Dermatology · 4

PDF

Works count: 42

Citation count: 2,464

H-index: 16

I10-index: 19